NVS - Novartis AG

NYSE - NYSE Delayed price. Currency in USD
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
6,955,000
6,955,000
24,021,000
8,072,000
11,732,000
Depreciation & amortisation
7,181,000
7,181,000
6,113,000
6,464,000
5,826,000
Deferred income taxes
1,416,000
1,416,000
2,119,000
1,807,000
1,793,000
Stock-based compensation
823,000
823,000
736,000
738,000
758,000
Change in working capital
-1,003,000
-1,003,000
241,000
-291,000
199,000
Accounts receivable
-589,000
-589,000
-389,000
137,000
-980,000
Inventory
-830,000
-830,000
81,000
-543,000
-382,000
Accounts payable
-48,000
-48,000
-21,000
-324,000
553,000
Other working capital
11,565,000
11,565,000
12,100,000
11,065,000
11,368,000
Other non-cash items
-59,000
-59,000
-530,000
-1,065,000
-124,000
Net cash provided by operating activities
14,236,000
14,236,000
15,071,000
13,650,000
13,625,000
Cash flows from investing activities
Investments in property, plant and equipment
-2,671,000
-2,671,000
-2,971,000
-2,585,000
-2,257,000
Acquisitions, net
-
-903,000
-
-9,964,000
-3,766,000
Purchases of investments
-34,816,000
-34,816,000
-16,594,000
-2,130,000
-530,000
Sales/maturities of investments
39,490,000
39,490,000
2,740,000
1,215,000
3,713,000
Other investing activities
-1,000
-1,000
-57,000
-59,000
-57,000
Net cash used for investing activities
1,468,000
1,468,000
4,208,000
-13,182,000
-2,226,000
Cash flows from financing activities
Debt repayment
-2,870,000
-2,870,000
-2,478,000
-2,315,000
-3,468,000
Common stock repurchased
-10,652,000
-10,652,000
-3,057,000
-2,842,000
-5,533,000
Dividends paid
-7,506,000
-7,506,000
-7,368,000
-6,987,000
-6,645,000
Other financing activities
55,000
55,000
94,000
-149,000
50,000
Net cash used provided by (used for) financing activities
-20,562,000
-20,562,000
-16,264,000
-2,158,000
-16,884,000
Net change in cash
-4,890,000
-4,890,000
2,749,000
-1,454,000
-2,159,000
Cash at beginning of period
12,407,000
12,407,000
9,658,000
11,112,000
13,271,000
Cash at end of period
7,517,000
7,517,000
12,407,000
9,658,000
11,112,000
Free cash flow
Operating cash flow
14,236,000
14,236,000
15,071,000
13,650,000
13,625,000
Capital expenditure
-2,671,000
-2,671,000
-2,971,000
-2,585,000
-2,257,000
Free cash flow
11,565,000
11,565,000
12,100,000
11,065,000
11,368,000